Joris Diels

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Multiple Myeloma

Tyrosine Kinase

Clinical Practice

Top Venues

Journal of comparative effectiveness research

Advances in therapy

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Heather Burnett, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Nieves Lopez-Muñoz
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison. Current medical research and opinion (2024)
Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Heather Burnett, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Nieves Lopez-Muñoz
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison. Current medical research and opinion 40 (9) (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Donna Reece, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric Ammann, Christoph Heuck, Colleen Kane, Anil Londhe, Steve Peterson, Ajai Chari
Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma. Current medical research and opinion (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Winfried H Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of comparative effectiveness research 13 (9) (2024)
Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Heather Burnett, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Nieves Lopez-Muñoz
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison. Current medical research and opinion 40 (9) (2024)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Petros Christopoulos, Nicolas Girard, Claudia Proto, Marta Soares, Pilar Garrido Lopez, Anthonie J van der Wekken, Sanjay Popat, Joris Diels, Claudio A Schioppa, Jan Sermon, Nora Rahhali, Corinna Pick-Lauer, Agnieszka Adamczyk, James Penton, Marie Wislez
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations. Cancers 15 (22) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Maximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, Mounzer Agha, Joris Diels, Francesca Ghilotti, Nolen J Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Henrik Sliwka, Jordan M Schecter, Carolyn C Jackson, Yunsi Olyslager, Muhammad Akram, Tonia Nesheiwat, Lenka Kellermann, Sundar Jagannath
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. Cancers 13 (23) (2021)